National Bank of Canada FI Sells 150,753 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

National Bank of Canada FI trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,518,286 shares of the biopharmaceutical company's stock after selling 150,753 shares during the quarter. National Bank of Canada FI owned 0.12% of Gilead Sciences worth $140,249,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. State Street Corp lifted its stake in shares of Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after acquiring an additional 841,776 shares during the period. Wellington Management Group LLP raised its holdings in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock worth $2,302,119,000 after purchasing an additional 574,421 shares during the period. Norges Bank bought a new stake in shares of Gilead Sciences in the 4th quarter valued at $1,789,254,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Gilead Sciences by 3.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company's stock worth $739,217,000 after buying an additional 249,804 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Gilead Sciences Stock Up 0.4 %

NASDAQ:GILD traded up $0.50 during trading hours on Thursday, hitting $112.39. 10,041,148 shares of the company traded hands, compared to its average volume of 7,317,884. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market cap of $139.94 billion, a PE ratio of 303.76, a PEG ratio of 0.71 and a beta of 0.32. The firm's 50-day simple moving average is $106.63 and its 200-day simple moving average is $95.52.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.81%. Gilead Sciences's dividend payout ratio is currently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Bank of America boosted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Finally, BMO Capital Markets raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $105.12.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.